EuropaBio calls for the removal of access barriers to personalized medicine

Trade group EuropaBio once again called on European policymakers to remove the hurdles preventing European patients’ access to personalized medicine (PM).

Biopharmaceutical companies face high costs of clinical development for regulatory approval against a backdrop of increasingly fragmented reimbursement systems and assessment mechanisms unfit for the specificities of personalized therapies, the association said.

These views were raised by EuropaBio at yesterday’s High-level Conference by the European Union’s Luxembourg Presidency on “Making Access to Personalized Medicine a Reality for Patients.” They build on EuropaBio’s White Paper on Personalized Medicine which identifies essential changes needed to successfully integrate personalized medicine approaches into existing health care systems. These changes refer to scientific, drug and diagnostic development frameworks, as well as product assessment and reimbursement.